This phase II trial aims to study the efficacy and safety of adjuvant Pyrotinib plus trastuzumab in patients with tumors \<8mm, node-negative, HER2-positive breast cancer.
Women aged 18-70 years old
Have finished radical operation
Histologically confirmed invasive ductal carcinoma (IDCA)
According to AJCC ,pT<8mm, pN0, no evidence for metastasis
pT≥8mm or node positive
Metastatic breast cancer
Any prior systemic or loco-regional treatment of breast cancer, including chemotherapy in 28 days
With a history of malignant tumor except uterine cervix cancer in situ or skin basal cell carcinoma
xuexin he
Lead sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor institution